Diseases, Conditions, Syndromes

T-cells with a license to kill viruses

A research group led by Kyoto University has produced the world's first pluripotent stem cell-derived killer T-cell drug to treat COVID-19. The University has filed a patent application ahead of full-scale drug development.

Oncology & Cancer

Overcoming the limits of immunotherapies

CAR-T cells are highly effective in treating selected blood cancers. However, challenges remain with this new therapy, which was first approved in 2017 in the U.S. and a year later in Europe for treating acute lymphoblastic ...

Immunology

T cells and aging: Unraveling the complexities of lifespan

Aging significantly impacts the immune system, notably through the involution of the thymus, which reduces T cell production. This decline weakens immune responses, making older adults more susceptible to infections and diseases. ...

Oncology & Cancer

How an effective cancer therapy may damage the heart

Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a protein receptor on T immune cells that prevents the cells from killing other cells, such as cancer cells. Blocking CTLA-4 with a specific antibody is an effective treatment ...

Oncology & Cancer

Blood test may guide use of multiple myeloma immunotherapy

A simple blood test that measures the number of lymphocytes, a type of white blood cell in the body, may predict whether people who have relapsed multiple myeloma are going to respond well to CAR-T immunotherapy, according ...

page 3 from 4